Accredited secondary HLH/MAS masterclass
Would you like to self-assess your knowledge before watching? Click here to access the quiz.
Important note for logged-out users: Please complete the full session and evaluation without exiting your browser. If you exit before finishing, you’ll need to restart from the beginning. We recommend logging in to avoid interruptions and preserve your progress.
To view this resource, please enable "Functional Cookies" using the cookie icon at the bottom left of your screen. Learn more about how we use cookies in our privacy policy.
“Early recognition and timely intervention are critical to improving outcomes in HLH/MAS.” Watch this EBAC-accredited masterclass, presented by Fabrizio de Benedetti, to deepen your understanding of the diagnosis, biomarkers, and treatment strategies for secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS). This three-part series offers expert insights into managing this often underdiagnosed, rapidly progressive, and life-threatening hyperinflammatory syndrome.
Watch now to:
- Recognize the urgency of HLH/MAS and its potential for rapid clinical progression
- Apply biomarker-driven stratification to assess disease severity and monitor treatment response
- Assess how targeted therapies, including IL-1 inhibitors and IFN-γ blockade, are reshaping the treatment landscape for both pediatric and adult patients
How much do you know about HLH/MAS? Answer these six questions to find out. We’ll ask you the questions again after you’ve watched the masterclass to see what you recall.
If you're having trouble accessing this quiz, try refreshing your browser. If the issue persists, please enable browser cookies and remove any ad blockers in your settings, and refresh the page again.
Meet the expert
Fabrizio de Benedetti, MD, PhD
Fabrizio de Benedetti is a pediatric rheumatologist who serves as Director of the Division of Rheumatology and Head of the Laboratory of Immuno-Rheumatology at Ospedale Pediatrico Bambino Gesù in Rome, Italy. He is also Professor of Pediatric Rheumatology at the Universities Tor Vergata and La Sapienza.
De Benedetti’s work focuses on both clinical and translational research in pediatric rheumatology. He has been the principal investigator for several pivotal phase 2/3 clinical trials of novel targeted therapies in pediatric rheumatic diseases, including Still’s disease, polyarticular juvenile idiopathic arthritis, macrophage activation syndrome, familial Mediterranean fever, mevalonate kinase deficiency, and tumor necrosis factor receptor–associated periodic syndrome.
Disclosures: Abbott, Bristol Myers Squibb, Novartis, Novimmune, Pfizer, Roche, and Sobi.
Developed independently by EPG Health, which received an educational grant from Sobi, awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.